Total Skin Electron Beam Radiation Therapy for Mycosis Fungoides

Reddy, S. Hari Krishna; Parker, Colleen M.; Shidnia, Homayoon; Gaffney, M G; Blyton, B D; Pruner, L M; Kalasinski, Lorrie A.

doi:10.1097/00000421-199204000-00005

Cited by 29 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge there have been no known clinical trials for the treatment of this group of PCTCL, as they are heterogeneous and infrequent. These include topical chemotherapy with agents like carmustine (BCNU) and nitrogen mustard (NM), [11] light psoralen ultraviolet (PUVA) therapy, [12] local [13] and generalized [14] superficial ionizing radiation, interferon therapy, [15] extracorporeal photochemotherapy also known as photopheresis, [16] retinoids, [17] monoclonal antibodies, [18] DABIL-2 toxin, [19] and systemic chemotherapy. [3] The most important clinical prognostic variables in patients with cutaneous T-cell lymphomas are the type of lesion and the percent of total skin surface involved, the nodal status, the visceral involvement, and the presence of lymphoma cells in the circulation.…”

Section: Complete Remission Of Previously Intractable Pctcl Of the Lomentioning

confidence: 99%

Complete Remission of Previously Intractable Peripheral Cutaneous T-Cell Lymphoma of the Lower Extremity Using Isolated Hyperthermic Limb Perfusion with Melphalan (1-Phenylalanine Mustard)

Paramo

Benavides

Tang

et al. 2004

Cancer Investigation

View full text Add to dashboard Cite

The patient is a 74-year-old woman first diagnosed with a peripheral cutaneous T-cell lymphoma (PCTCL) in April of 1994. Initially she presented with subcutaneous indurated areas in the right forearm, scapula, and submadibular region. After chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), she went into remission for 2 years before relapse of her PCTCL localized to the right lower extremity. Persistent isolated disease in the extremity since then led to numerous chemotherapy regimens and localized radiation therapy. Due to dramatic limb threatening progression of the disease in 2001, she underwent isolated hyperthermic limb perfusion with melphalan (1-phenylalanine mustard). Although limb preservation could not be achieved, this treatment resulted in complete clinical and pathological regression of the lesions of the perfused extremity.

show abstract

Section: Complete Remission Of Previously Intractable Pctcl Of the Lomentioning

confidence: 99%

Complete Remission of Previously Intractable Peripheral Cutaneous T-Cell Lymphoma of the Lower Extremity Using Isolated Hyperthermic Limb Perfusion with Melphalan (1-Phenylalanine Mustard)

Paramo

Benavides

Tang

et al. 2004

Cancer Investigation

View full text Add to dashboard Cite

show abstract

“…have reported a cure rate of 95–100% with TSEI. The probability of complete remission is high with TSEI and it offers good palliation in advanced disease 13,14 . Of our 11 evaluable patients, 10 (90.9%) showed complete remission following TSEI and five (45%) were without disease at 5 years of follow‐up.…”

Section: Discussionmentioning

confidence: 87%

Cutaneous T‐cell lymphoma treated with electron beam irradiation in Indian patients

et al. 2001

View full text Add to dashboard Cite

show abstract

“…Radiation therapy also is effective treatment in the early and advanced stages of MF. Several successful trials have used radiation therapy in combination with other therapies, such as PUVA and systemic and topical chemotherapy with total-skin electron beam therapy (Reddy et al, 1992). Chemotherapy also plays a role in MF treatment, often as a single agent of pulse steroids, alkylating agents, or methotrexate (Rosen & Foss, 1995).…”

Section: Low-grade T-cell Non-hodgkin's Lymphomamentioning

confidence: 99%

Denileukin Diftitox as Novel Targeted Therapy in Non-Hodgkin's Lymphoma

Walker¹,

Dang²

2004

Clinical Journal of Oncology Nursing

View full text Add to dashboard Cite

Non-Hodgkin's lymphoma (NHL) is a complex group of hematologic malignancies. The majority are B-cell lineage, with 10%-20% arising from T-cell lineage. Detailed knowledge of the subtypes and staging of NHL is essential to plan treatment and provide effective management of treatment-related side effects. Although numerous regimens have demonstrated efficacy in the treatment of NHL, some subtypes of lymphomas generally are not curable. The recent development of targeted therapies such as denileukin diftitox (Ontak, Ligand Pharmaceuticals, Inc., San Diego, CA) has resulted in potentially significant advances in the treatment of NHL. Oncology nurses must gain a better understanding of the unique mechanism of action of this agent and its side effects to successfully manage patients being treated with this novel therapy.

show abstract

Total Skin Electron Beam Radiation Therapy for Mycosis Fungoides

Cited by 29 publications

References 0 publications

Complete Remission of Previously Intractable Peripheral Cutaneous T-Cell Lymphoma of the Lower Extremity Using Isolated Hyperthermic Limb Perfusion with Melphalan (1-Phenylalanine Mustard)

Complete Remission of Previously Intractable Peripheral Cutaneous T-Cell Lymphoma of the Lower Extremity Using Isolated Hyperthermic Limb Perfusion with Melphalan (1-Phenylalanine Mustard)

Cutaneous T‐cell lymphoma treated with electron beam irradiation in Indian patients

Denileukin Diftitox as Novel Targeted Therapy in Non-Hodgkin's Lymphoma

Contact Info

Product

Resources

About